Scandion Oncology is a pioneering clinical-stage biotechnology company focused on tackling cancer drug resistance. They are dedicated to discovering and developing innovative medicines that effectively combat cancers that have become resistant to existing treatment options. With a strong commitment to improving patients' lives, Scandion Oncology aims to enhance the efficacy and duration of current cancer therapies, thereby offering hope to individuals who face a high risk of mortality from their cancer diagnoses.

Recognizing the urgent need for customized solutions to address drug resistance, Scandion Oncology takes a tailored approach to this complex medical challenge. Their groundbreaking medicines have the potential to make a significant impact on a global scale, as nearly 10 million patients worldwide succumb to treatment-resistant cancers each year. By developing oral add-on drugs that can complement existing leading therapies, Scandion Oncology aims to target multiple cancer types, both medically and commercially.

Their vision is to successfully overcome cancer drug resistance, providing improved outcomes for cancer patients and their families. For more information and updates, visit Scandion Oncology's website